Yahoo Finance • 2 months ago
DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued Enrollment Multip... Full story
Yahoo Finance • 2 months ago
A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Welln... Full story
Yahoo Finance • 3 months ago
A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourt... Full story
Yahoo Finance • 3 months ago
SAN DIEGO, July 14, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced positive interim safety and... Full story
Yahoo Finance • 3 months ago
SAN DIEGO - Daré Bioscience, Inc. (NASDAQ:DARE), a biotechnology company with a market capitalization of $21.15 million, has received a $6 million non-dilutive funding installment to support the development of its contraceptive drug delive... Full story
Yahoo Finance • 3 months ago
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced the receipt of a $6 millio... Full story
Yahoo Finance • 3 months ago
Dare Bioscience, Inc. (NASDAQ:DARE) reported the results of its 2025 annual meeting of stockholders, which was reconvened Wednesday after an earlier adjournment due to lack of quorum. The information is based on a press release statement i... Full story
Yahoo Finance • 4 months ago
SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that the company’s 2025 ann... Full story
Yahoo Finance • 5 months ago
Creates commercial opportunity in the estimated up to $4.5 billion compounded hormone therapy market, enabling women to access an evidence-based solutionFour on-market products will accelerate revenue generation and provide path to profita... Full story
Yahoo Finance • 6 months ago
Presentation will focus on corporate communications strategies for unveiling an innovative expanded business strategyDaré recently announced its new dual-path approach for its proprietary Sildenafil Cream formulation and is targeting avail... Full story
Yahoo Finance • 6 months ago
Enables women to access a solution that they want and needCreates an opportunity to accelerate revenue generation from this proprietary formulation Daré expects to start recording revenue and cash flow in the 4th quarter of this year Conf... Full story
Yahoo Finance • 8 months ago
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management Essentially all cervical cancer cases worldwide are caused b... Full story
Yahoo Finance • 2 years ago
SAN DIEGO and MORRISVILLE, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Premier Research International, LLC, a global clinical research, product development, and... Full story
Yahoo Finance • 2 years ago
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery... Full story
Yahoo Finance • 2 years ago
Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of $1.8 million triggered by achievement of first commercial milestone under license agreement with OrganonOvaprene®: commenceme... Full story
Yahoo Finance • 2 years ago
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, Novembe... Full story
Yahoo Finance • 2 years ago
Additional Analyses of Phase 2b Data Conducted in Population of Study Participants with Female Sexual Interest/Arousal Disorder (FSIAD), With Primary Complaint of Arousal Dysfunction Achieved Statistical Significance and Clinically Meanin... Full story
Yahoo Finance • 2 years ago
SAN DIEGO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the first shipment of XACIATOTM [pronounced zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2%... Full story
Yahoo Finance • 2 years ago
SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Dr. Andrew Goldstein, Daré Medical Advisor, will present at the 2023 Annual Meeting of The Me... Full story
Yahoo Finance • 2 years ago
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following... Full story